

1. Shimizu, T., Tomogane, M., Miyashita, M., Ukimura, O. & Ashihara, E. Low dose gemcitabine increases the cytotoxicity of human V γ 9V δ 2 T cells in bladder cancer cells in vitro and in an orthotopic xenograft model. *Cell* 173, e1424671 (2018) doi: 10.1080/2162402X.2018.1424671.
2. Murakami, S. et al. Combining T-cell-based immunotherapy with venetoclax elicits synergistic cytotoxicity to B-cell lines in vitro. *Hematological Oncology* 38, 705–714 (2020) doi: 10.1002/hon.2794.
3. Kondo, Y. et al. Improving function of cytotoxic T-lymphocytes by transforming growth factor- β inhibitor in oral squamous cell carcinoma. *Cancer Science* 112, 4037–4049 (2021) doi: 10.1111/cas.15081.
4. Tomogane, M. et al. Human V γ 9V δ 2 T cells exert anti-tumor activity independently of PD-L1 expression in tumor cells. *Biochemical and Biophysical Research Communications* 573, 132–139 (2021) doi: 10.1016/j.bbrc.2021.08.005.
5. Nishio-Nagai, M., Suzuki, S., Yoshikawa, K., Ueda, R. & Kazaoka, Y. Adoptive immunotherapy combined with FP treatment for head and neck cancer: An in vitro study. *Int J Oncol* 51, 1471–1481 (2017) doi: 10.3892/ijo.2017.4142.
6. Noguchi, J. et al. Successful activation of rat T lymphocytes by sperm specific antigens in vitro. *Journal of Reproduction and Development* 66, 599–605 (2020) doi: 10.1262/jrd.2020-106.
7. Masaki, A. et al. Autologous Tax-Specific CTL Therapy in a Primary Adult T Cell Leukemia/Lymphoma Cell-Bearing NOD/Shi-*scid*, IL-2R γ null Mouse Model. *J. Immunol.* 191, 135 (2013) doi: 10.4049/jimmunol.1202692.
8. Narita, T. et al. HTLV-1 bZIP Factor-Specific CD4 T Cell Responses in Adult T Cell Leukemia/Lymphoma Patients after Allogeneic Hematopoietic Stem Cell Transplantation. *J. Immunol.* 192, 940 (2014) doi: 10.4049/jimmunol.1301952.
9. Abe, Y. et al. Application of gamma-delta T cells obtained by ascites filtration for immunotherapy against malignant refractory ascites. *Annals of Cancer Research and Therapy* 27, 73–79 (2019) doi: 10.4993/acrt.27.73.
10. Abe, Y. et al. Possible Application of Ascites-infiltrating Gamma-delta T Cells for Adoptive Immunotherapy. *Anticancer Res* 38, 4327–4331 (2018) doi: 10.21873/anticancer.12732.
11. Takahashi, N. et al. Construction of in vitro patient-derived tumor models to evaluate anticancer agents and cancer immunotherapy. *Oncol Lett* 21, 406 (2021) doi: 10.3892/ol.2021.12667.
12. Todo, S. et al. A pilot study of operational tolerance with a regulatory T-cell-based cell therapy in living donor liver transplantation. *Hepatology* 64, 632–643 (2016) doi: 10.1002/hep.28459.

13. Abe, Y., Kobayashi, H., Akizawa, Y., Ishitani, K. & Matsui, H. Role of IL-18 on the activation of V δ 2+ T cells – For the development of novel cancer immunotherapy –. *Annals of Cancer Research and Therapy* 26, 71–76 (2018) doi: 10.4993/acrt.26.71.
14. Inoo, K. et al. Immunological quality and performance of tumor vessel-targeting CAR-T cells prepared by mRNA-EP for clinical research. *Molecular Therapy - Oncolytics* 3, 16024 (2016) doi: 10.1038/mto.2016.24.
15. Suzuki, S. et al. Tax is a potential molecular target for immunotherapy of adult T-cell leukemia/lymphoma. *Cancer Science* 103, 1764–1773 (2012) doi: 10.1111/j.1349-7006.2012.02371.x.
16. Kimura, H. et al. Randomized controlled phase III trial of adjuvant chemo-immunotherapy with activated killer T cells and dendritic cells in patients with resected primary lung cancer. *Cancer Immunology, Immunotherapy* 64, 51–59 (2015) doi: 10.1007/s00262-014-1613-0.
17. Sasawatari, S., Okamoto, Y., Kumanogoh, A. & Toyofuku, T. Blockade of N-Glycosylation Promotes Antitumor Immune Response of T Cells. *J. Immunol.* 204, 1373 (2020) doi: 10.4049/jimmunol.1900937.
18. Morisaki, T. et al. NKG2D-directed Cytokine-activated Killer Lymphocyte Therapy Combined with Gemcitabine for Patients with Chemoresistant Metastatic Solid Tumors. *Anticancer Res* 34, 4529 (2014).
19. Eom, H.-S. et al. Phase I Clinical Trial of 4-1BB-based Adoptive T-Cell Therapy for Epstein-Barr Virus (EBV)-positive Tumors. *J Immunother* 39, 140–148 (2016) doi: 10.1097/CJI.000000000000113.
20. Tsuda, J. et al. Involvement of CD56^{bright}CD11c⁺ Cells in IL-18–Mediated Expansion of Human $\gamma\delta$ T Cells. *J. Immunol.* 186, 2003 (2011) doi: 10.4049/jimmunol.1001919.
21. Liu, H. et al. Comparative study of different procedures for the separation of peripheral blood mononuclear cells in cytokine-induced killer cell immunotherapy for hepatocarcinoma. *Tumor Biology* 36, 2299–2307 (2015) doi: 10.1007/s13277-014-2837-5.
22. Miyashita, M. et al. Sphere-derived Prostate Cancer Stem Cells Are Resistant to $\gamma\delta$ T Cell Cytotoxicity. *Anticancer Res* 40, 5481–5487 (2020) doi: 10.21873/anticancer.14559.
23. Zeng, G. et al. Cryopreservation of peripheral blood mononuclear cells using uncontrolled rate freezing. *Cell and Tissue Banking* 21, 631–641 (2020) doi: 10.1007/s10561-020-09857-w.

24. Takagi, M. et al. Haploinsufficiency of TNFAIP3 (A20) by germline mutation is involved in autoimmune lymphoproliferative syndrome. *Journal of Allergy and Clinical Immunology* 139, 1914–1922 (2017) doi: 10.1016/j.jaci.2016.09.038.
25. Watanabe, K. et al. CD137-guided isolation and expansion of antigen-specific CD8 cells for potential use in adoptive immunotherapy. *International Journal of Hematology* 88, 311–320 (2008) doi: 10.1007/s12185-008-0134-z.
26. Kobayashi, H., Tanaka, Y., Yagi, J., Minato, N. & Tanabe, K. Phase I/II study of adoptive transfer of $\gamma\delta$ T cells in combination with zoledronic acid and IL-2 to patients with advanced renal cell carcinoma. *Cancer Immunology, Immunotherapy* 60, 1075–1084 (2011) doi: 10.1007/s00262-011-1021-7.
27. Suzuki, T. et al. The antitumour effect of $\{\gamma\delta\}$ T-cells is enhanced by valproic acid-induced up-regulation of NKG2D ligands. *Anticancer Res* 30, 4509–4513 (2010).

Alys 705

1. Morokawa, H. et al. Autologous non-human primate model for safety assessment of piggyBac transposon-mediated chimeric antigen receptor T cells on granulocyte–macrophage colony-stimulating factor receptor. *Clinical & Translational Immunology* 9, e1207 (2020) doi: 10.1002/cti2.1207.
2. Kubo, H. et al. Development of non-viral, ligand-dependent, EPHB4-specific chimeric antigen receptor T cells for treatment of rhabdomyosarcoma. *Molecular Therapy - Oncolytics* 20, 646–658 (2021) doi: 10.1016/j.omto.2021.03.001.
3. Nakamura, K. et al. Autologous antigen-presenting cells efficiently expand piggyBac transposon CAR-T cells with predominant memory phenotype. *Molecular Therapy - Methods & Clinical Development* 21, 315–324 (2021) doi: 10.1016/j.omtm.2021.03.011.
4. Yagyu, S. et al. A lymphodepleted non-human primate model for the assessment of acute on-target and off-tumor toxicity of human chimeric antigen receptor-T cells. *Clinical & Translational Immunology* 10, e1291 (2021) doi: 10.1002/cti2.1291.
5. Suematsu, M. et al. PiggyBac Transposon-Mediated CD19 Chimeric Antigen Receptor-T Cells Derived From CD45RA-Positive Peripheral Blood Mononuclear Cells Possess Potent and Sustained Antileukemic Function. *Frontiers in Immunology* 13, (2022) doi: doi.org/10.3389/fimmu.2022.770132.
6. Mie, K. et al. Influence of transfusion of lymphokine-activated T killer cells on inflammatory responses in dogs after laparotomy. *J Vet Med Sci* 78, 579–585 (2016) doi: 10.1292/jvms.15-0626.

7. Mie, K., Shimada, T., Akiyoshi, H., Hayashi, A. & Ohashi, F. Change in peripheral blood lymphocyte count in dogs following adoptive immunotherapy using lymphokine-activated T killer cells combined with palliative tumor resection. *Veterinary Immunology and Immunopathology* 177, 58–63 (2016) doi: 10.1016/j.vetimm.2016.06.007.